NICE ruling on prostate cancer drug questioned

cancer reaserch

Scientists have expressed their disappointment over a preliminary decision by the National Institute of Health and Care Excellence not to offer a life-extending drug to prostate cancer patients until after they have received chemotherapy.

You need to be an HSJ subscriber to read more


Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to
  • The HSJ app

Enquire about multi-user access